Wall Street has recorded moderate gains on the first day of March, with crude prices being the main catalyst for the stock exchanges. Meanwhile, there are several stocks gaining today, some of which are Workday Inc (NYSE:WDAY), Exelixis, Inc. (NASDAQ:EXEL), JD.Com Inc (ADR) (NASDAQ:JD), Hertz Global Holdings Inc (NYSE:HTZ), and Ion Geophysical Corp (NYSE:IO). In this article, we’ll take a closer look at the developments behind the moves registered by these stocks and assess the relevant hedge fund sentiment towards them.
We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).
Workday Inc (NYSE:WDAY)’s stock is nearly 14% higher on the back of the company posting its financial results for the fourth quarter and full 2016 fiscal year. For the quarter ended January 31, Workday reported revenue growth of 42.9% year-over-year to $323.4 million, while its loss narrowed to $0.01 per share from $0.06 per share a year earlier. Moreover, the results exceeded analysts’ estimates by $0.04 in EPS and by $3.77 million in revenue. In addition to that, the provider of enterprise cloud applications for finance and human resources said it reached subscription revenue of $261.8 million, an increase of 44% for the fiscal year. For the current quarter, the company forecasts revenue in the range of $337 million to $339 million and fiscal year 2017 revenue of between $1.54 billion and $1.55 billion, largely in-line with estimates. A total of 24 funds from our database held 6.1% of Workday Inc (NYSE:WDAY)’s outstanding stock at the end of the fourth quarter, down by four funds over the quarter. David Goel and Paul Ferri’s Matrix Capital Management was among the believers in our database, with 3.96 million shares held at the end of December.
Next up is Exelixis, Inc. (NASDAQ:EXEL), whose shares are up by 4% after the company revealed a narrower loss than expected for the fourth quarter. Exelixis reported a loss of $0.19 per share on revenue of $9.9 million, beating analysts’ estimates by $0.03 per share and $1.74 million, respectively. The cancer drug developer expects operating expenses of between $240 and $270 million in 2016, including about $30 million of incremental, non-cash, stock-based compensation expenses. In other news, Exelixis and Ipsen have announced an exclusive licensing agreement for marketing and development of cabozantinib , which is a leading oncology drug. The agreement stipulates that Ipsen will have exclusive marketing rights to cabozantinib outside the United States, Canada and Japan, while Exelixis will maintain exclusive commercial rights to cabozantinib in the United States and Canada. The two sides will continue to negotiate over the rights to the drug in the Land of the Rising Sun.
Of the 730 elite funds that we track, 17 of them were long Exelixis, Inc. (NASDAQ:EXEL) on December 31, owning 7.20% of the company’s float. Among the believers is Kenneth Tropin‘s Graham Capital Management, with a holding of 13.22 million shares.